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Abstract
Introduction The difference in breast cancer incidence and
prognosis between ethnic groups seeks an explanation. We
have recently shown that Swedish women are two to three times
more likely to be diagnosed with breast cancer compared with
Singaporean women. In the present paper, we compare breast
cancer survival in the two countries.
Methods We compared the survival of 10,287 Singaporean
women and 17,090 Swedish women with breast cancer.
Relative survival ratios were used to describe the prognosis in
the two populations. A Poisson regression model was used to
calculate relative risks for different follow-up periods, age
groups, time of diagnosis and disease stages.
Results The majority of the Swedish women had local cancer
(80%) compared with Singaporean women (51%). The overall
5-year relative survival of the Swedish women appeared better
(80%) than that of the Singaporean women (70%). A similar
survival pattern was observed, however, between the two
countries in a stage-by-stage comparison. Survival improved for
all women in Singapore over the two decades, but only in the
premenopausal women in Stockholm. In 1980 to 1989,
premenopausal Singaporean women had 27% increased risk of
death compared with Swedish women, adjusted for stage and
year of follow-up, while the postmenopausal women had 48%
increased risk. In 1990 to 1999, this risk decreased by 19% and
22% for the premenopausal and postmenopausal Singaporean
women compared with the Swedish women.
Conclusions The stage-dependent prognosis was similar for
Singaporean women and for Swedish women. Singaporean
women, both premenopausal and postmenopausal, had
pronounced improvement in prognosis over the calendar
periods, probably contributed by marked economic
improvement, leading to better medical facilities and
management with increased awareness of patients to diagnosis
and treatment, as well as improved treatment options.
Improvement seen only in the premenopausal women in
Stockholm was probably due to improved treatment options.
Introduction
The study of ethnic differences in breast cancer survival is lim-
ited except for those between Afro-American women, Asian-
American women and Caucasian American women. In the
United States, Afro-American women are known to have a
worse outcome compared with Caucasian American women.
This has been attributed to increased diagnosis of late-stage
breast cancers, which could be explained by delayed diagno-
sis reflecting the socioeconomic status, cultural beliefs,
access to healthcare [1], and the proportion of estrogen
receptor (ER)-negative tumors in the Afro-American women
[2]. In US women diagnosed with breast cancer from 1992 to
1998, a positive ER was found in 81% of non-Hispanic Whites
and in 66% of Afro-Americans [3]. ER-negative breast cancer,
however, seems to be influenced by parity and age at first
birth. It has been reported that increased parity at an early age
is associated with ER-negative breast cancer [4]. Early age at
first birth could also have an adverse effect on the prognosis
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of breast cancer [5] due to the interplay of hormonal factors in
tumor biology and prognosis. More Afro-American women
have children early (<20 years old) [6,7] and tend to have
higher parity compared with the non-Hispanic White women
[8].
The ethnic disparity in incidence, mortality and survival is evi-
dent in the United States, where breast cancer is predomi-
nantly a postmenopausal disease in the Caucasian American
population [2,9] but a premenopausal disease in Asian or non-
Caucasian populations [10-12]. We have recently shown that
Swedish women are two or three times more likely to be diag-
nosed with postmenopausal breast cancer compared with
Singaporean women [13]. The difference was most pro-
nounced for older birth cohorts, where it is likely that Singapo-
rean women protected themselves from postmenopausal
breast cancer by younger age at first birth and giving birth to
many children. The difference in childbearing practices may be
of importance for breast cancer prognosis.
Sweden is relatively homogeneous in ethnic stock, while the
Singaporean population is multiracial with a prominent Chi-
nese population (76%), 13% Malays and 7% Indians [14].
Over the past four to five decades, Sweden has enjoyed high
socioeconomic conditions while Singapore has undergone
significant economic restructuring in the 1980s and 1990s.
Stockholm and Singapore in recent times have become very
similar, being modern city-states with high socioeconomic sta-
tus, education and living standards and good accessible
healthcare systems [15,16]. Sweden has a nationwide mam-
mographic screening program, established since the 1980s.
In Singapore, screening was opportunistic until the Singapore
Breast Screening program was launched in 2002. Screening
mammography has again been proven in more recent studies
to decrease mortality in breast cancer [17-20].
These similarities and differences make the study of breast
cancer prognosis important. Such study may highlight biolog-
ical and nonbiological reasons for any difference in the prog-
nosis between Singapore and Sweden. In this paper, we aim
to compare the survival in women diagnosed with breast can-
cer in Singapore and in Sweden in relation to important clinical
prognostic markers for breast cancer. We also studied how
the trends in survival patterns of the breast cancer patients
relate to the change in incidence and mortality.
Materials and methods
Study population
All cases of invasive breast cancer diagnosed from 1 January
1980 to 31 December 1999 were obtained from the Singa-
pore and Stockholm cancer registries. Patients with a previous
malignancy, including contralateral breast cancer, and those
diagnosed with breast cancer at autopsy (death certificate
only) were excluded from the study. Follow-up was performed
until 31 December 2005 by matching with the national death
register. The cause of death was coded in accordance with
the International Classification of Diseases and Causes of
Death ICD9. The ethical committees at the National University
of Singapore and Karolinska Institutet accepted the study
without any restrictions. This is normal when de-identified
material is used.
Singapore Cancer Registry
The Singapore Cancer Registry is a population-based registry
that was started in 1968. It receives voluntary notifications of
incident cancers from all medical practitioners and pathology
laboratories, as well as reviews, death certificates and hospital
discharges for all patients. Staff of the Registry also reviewed
cancer patient hospital discharges and death certificates. The
completeness of reporting is high: 96% in the 1970s and
close to 100% in the 1990s. The proportion of death-certifi-
cate-only notifications was 4.2% for the period 1968 to 1977,
1.0% for 1993 to 1997 and 0.9% for 1998 to 2002 [21]. In
total, 4 million individuals inhabit Singapore [14] – 10,287
women diagnosed with breast cancer between 1980 and
1999 were identified and included in the study [21].
Stockholm Breast Cancer Registry
The Stockholm Breast Cancer Registry was started in 1977
and receives notification of newly diagnosed cases of breast
cancer at all departments of oncology and surgery in Stock-
holm County, which is inhabited by 1.7 million individuals.
There were 17,090 women diagnosed with breast cancer
recorded in the calendar period 1980 to 1999. None of them
were death-certificate-only diagnoses.
Stage information
The stage of the breast cancer in the Singapore Cancer Reg-
istry was classified as localized cancer, regional spread and
distant metastases based on the notification forms before
2001. Cancers are staged as local if they are confined entirely
to the breast. Regional cancers are those that have extended
beyond the limits of the breast directly into surrounding tissues
or organs, or into lymph nodes in the region. Distant cancers
are those that have spread beyond these locations. No
attempt was made to access the extent of localized invasion or
the number of regional lymph nodes involved.
Stage information in the Stockholm registry was available
according to the TMN staging system: tumor stage, lymph
node stage and metastatic spread. This information was
reclassified, using the Surveillance, Epidemiology and End
Results Comparative Staging Guide for Cancer [22], to be
comparable with the Singapore cohort – as localized disease
where breast cancer was only identified in the mammary
gland; regional disease when there is direct extension to sur-
rounding tissues or organs, or axillary lymph nodes are
affected; and distant metastasis.Available online http://breast-cancer-research.com/content/11/1/R4
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Statistical analysis
Age at diagnosis was categorized into six age groups (<35
years, 35 to 44 years, 45 to 54 years, 55 to 64 years, 65 to 74
years, 75+ years) and the period of diagnosis divided into two
10-year periods (1980 to 1989 and 1990 to 1999) to identify
change over time; 1990 was selected because the early
1990s were when the use of tamoxifen became widely
accepted and adjuvant treatment was more standardized in
Singapore.
Descriptive prognostic comparisons between Singaporean
women and Swedish women were performed by relative sur-
vival analyses. Relative survival ratios were computed by taking
the ratio of observed survival to expected survival, accounting
for the competing causes of death. The expected survival
probabilities were calculated using Ederer II method [23]
derived from the general female population from Singapore
and Stockholm, respectively, similar to the breast cancer
patients in terms of attained age and calendar period of diag-
nosis. In order to compare the survival between the two coun-
tries, cumulative relative survival ratios were age-standardized
to the world standard cancer population [24]. A 3-year central
moving average for the 5-year relative survival ratios at each
calendar year of diagnosis was used to depict the trend across
the calendar periods. A Poisson regression model was also
used to calculate the excess hazards of death, taking into
account the age, disease stage, period of diagnosis, country
and years of follow-up. Interactions between country and the
age of diagnosis, and between the calendar period and the
age of diagnosis, were also analyzed. Two age groups (50
years old and >50 years old) were used to represent the pre-
menopausal and postmenopausal age groups in this analysis.
The incidence rates were calculated using the number of inva-
sive breast cancer cases out of the total female population of
each country for each time period. The cause of death informa-
tion was used only to calculate the cause-specific mortality
rate, which is the total of breast cancer deaths divided by the
total female population of each country. Five-year incidence
and mortality rates were reported and were age-standardized
to the world standard population [24]. STATA8.2 (StataCorp.
College Station, TX: Stata Corporation) was used for the sta-
tistical analyses.
Results
Table 1 presents the characteristics of the women with breast
cancer. At the end of 2005, 9,330 (55%) of the Swedish
women and 4,782 (46%) of the Singaporean women had
died. The median age at diagnosis was stable within each
country over the years of diagnosis; however, the Singaporean
women were more than a decade younger than those in Stock-
holm. Stage information was only available for two-thirds of the
Singapore cohort. The Swedish women were followed up for
a median of 8.7 years (range 0.003 to 26.0 years) while the
Singaporean women were followed up for 7.7 years (range
0.003 to 26.9 years)
Overall survival
The overall relative survival for women diagnosed with breast
cancer from 1980 to 1999 appeared better for the Swedish
cohort, where the Swedish women constantly outperformed
the Singaporean women at each year of follow-up (Figure 1).
The overall age-standardized 5-year relative survival for Singa-
porean women and for Swedish women was significantly dif-
ferent at 70% and 80%, respectively (Table 2).
Survival by stage
The majority of Swedish patients were diagnosed with a local-
ized cancer while only about one-half of the Singaporean
women had localized cancer (Table 1). Over the past 20 years
there has been a small increase in women presenting with
localized disease with a larger corresponding decrease in
regional disease in the Singaporean women; the metastatic
cases remained fairly constant (Table 1). When all of the
women diagnosed in 1980 to 1999 were stratified by the
stage of breast cancer, there was no difference in the relative
survival between the two cohorts (Figure 2).
Survival by period of diagnosis
The 5-year age-standardized relative survival ratio was used to
compare the survival by the period of diagnosis between the
two cohorts. In the 1980s the Singaporean women showed an
improvement in survival across all stages, most marked in
those with regional disease (with improvement of almost
20%); a smaller improvement was seen in the Swedish
women with the same stage. Singaporean women diagnosed
with local cancer and regional cancer had poorer survival than
the Swedish women (Table 2 and Figure 3).
In the 1990s survival among the Singaporean women with
localized cancer and regional cancer improved and was com-
parable with the Swedish women. In addition, these Singapo-
rean women with local cancer showed a marginal survival
advantage over the Swedish cohort in the later period.
Survival by age group
Singaporean women were diagnosed with breast cancer ear-
lier in life than the Swedish women; they were on average 10
years younger. While 52% of the Singaporean women diag-
nosed with breast cancer were 50 years old or younger, only
25% of the Swedish women were 50 years old or younger
(Table 1). Over the two decades, the median age in the Stock-
holm women decreased from 64 to 61 years while it remained
stable at 50 years old for the Singaporean women. The prog-
nostic outlook was more optimistic for women with breast can-
cer when they were between 35 and 75 years old. This was
consistent in both countries (Table 3).Breast Cancer Research    Vol 11 No 1    Tan et al.
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Poisson regression
Table 3 presents the risk of death of the women taking age,
disease stage, period of diagnosis and years of follow-up into
account in each country. As expected, the stage of cancer is
an important predictor of survival. The risk of death was
decreased in the later period for both countries and improve-
ment was greater in the Singaporean women. As there was a
significant interaction between the age at diagnosis and the
period of diagnosis (P = 0.008), comparison between the two
populations was performed stratified by the age and period of
diagnosis (Table 4).
In 1980 to 1989 premenopausal Singaporean women had
26% increased risk of death compared with the women in
Stockholm, adjusted for stage and year of follow-up, while the
postmenopausal women had 48% increased risk. In 1990 to
1999 the Singaporean women experienced a decreased risk
of death of 19% and 22%, respectively, for the premenopau-
sal women and the postmenopausal women compared with
the Swedish women (Table 4).
In Stockholm, survival improved only in the premenopausal
women over the two decades (hazard ratio = 0.74, P < 0.001).
In Singapore, the improvement was for all women over the
same period (hazard ratio = 0.51 and hazard ratio = 0.54 for
premenopausal women and postmenopausal women, P  <
0.0001 and P < 0.001, respectively; data not shown).
Survival in comparison with incidence and mortality 
rates
The incidence rate of breast cancer in Singaporean women
has more than doubled during the period of study (1980 to
1999). In contrast, the increase in incidence in the Swedish
women was only modest. The 5-year cause-specific mortality
Table 1
Characteristics of the Stockholm and Singapore breast cancer cohorts
Characteristic Stockholm Breast Cancer Registry Singapore Cancer Registry
Period of diagnosis 1980 to 1999 1980 to 1999
Number of breast cancer cases 17,090 10,287
1980 to 1989 (%) 7,932 (46) 3,135 (30)
1990 to 1999 (%) 9,148 (53) 7,152 (70)
Median age at diagnosis (years) 62 50
Standard deviation 14 13
Range (years) 18 to 101 12 to 98
Diagnosed  50 years old (%) 4,247 (25) 5,360 (52)
Diagnosed >50 years (%) 12,843 (75) 4,927 (48)
Number of women with information on disease stagea (%) 16,869 (99) 6,569 (64)
1980 to 1989
Local cancer (%) 6,047 (77) 1,090 (48)
Regional cancer (%) 1,667 (21) 961 (43)
Distant cancer (%) 165 (2) 196 (9)
1990 to 1999
Local cancer (%) 7,387 (82) 2,283 (53)
Regional cancer (%) 1,358 (15) 1,692 (39)
Distant cancer (%) 245 (3) 347 (8)
Estrogen receptor status
Positive 9,874 (77) Not available
Negative 2,984 (33) Not available
Number of deaths (%) 9,330 (55) 4,782 (46)
Number of breast cancer deaths (%) 4,050 (24) 2,684 (26)
aInvasive cancers are local stage if they are confined entirely to the breast. Regional cancers are those that have extended beyond the limits of the 
breast directly into surrounding tissues or organs, or into lymph nodes in the region. Distant cancers are those that have spread beyond these 
localizations.Available online http://breast-cancer-research.com/content/11/1/R4
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rate was constant in the Singaporean women from 1985 to
1999 (Figure 4). The mortality rate for the Swedish women
also remained relatively constant over the period. The marked
improvement in relative survival in the Singaporean women
over the two decades is consistent with the discrepancies of
the incidence and mortality rates described; the survival in the
Swedish women was stable.
Discussion
Singaporean women diagnosed with breast cancer experi-
enced an overall poorer survival compared with their Swedish
counterparts during 1980 to 1999. This poorer survival was
confounded by the stage of breast cancer, however, as sur-
vival was comparable between the two ethnically different
cohorts when stratified by stage. The difference in survival was
seen mainly in the regional group in the earlier period, and this
converged in the more recent period. Notably, the improve-
ment in survival over the years was marked for the Singapo-
rean women – whereas survival was relatively stable in
Stockholm in the postmenopausal women, with improvements
only in the premenopausal women.
Confounding factors such as registry completeness, stage
migration and distribution, diagnostic improvements and lead-
time bias have to be considered when analyzing trends in can-
cer survival. The strengths of our study include the large
number of cases, from population-based registries that report
high levels of reliability [21,25]. Women in both countries have
individual unique national registration numbers that allow for
accurate personal data collection, where women with bilateral
breast cancers or multiple cancers can be excluded from the
study. The study also extends over two decades, which was
probably long enough to observe differences and allow the
study of trends.
Incomplete disease stage information for one-third of women
in Singapore is a limitation of the present paper. To our knowl-
edge, every effort has been put in to ensure the completeness
of cancer reporting over the years. Clinical staging information,
which used to be reported voluntarily, could contribute to the
lack of information. There is now a follow-up mechanism by the
Table 2
Overall and 5-year age standardized relative survival of women with breast cancer in the Stockholm and Singapore cohorts
Characteristic Stockholm Breast Cancer Registry Singapore Cancer Registry
% 95% confidence interval % 95% confidence interval
5-year survival rates
Overall observed survival 72 71 to 74 64 62 to 66
Overall relative survival 80 78 to 82 70 67 to 73
Specific 5-year relative survival
Local
1980 to 1989 88 85 to 91 81 71 to 89
1990 to 1999 88 85 to 90 90 85 to 95
Regional
1980 to 1989 58 51 to 65 47 37 to 57
1990 to 1999 64 57 to 71 68 61 to 75
Distant
1980 to 1989 19 6 to 37 21 8 to 39
1990 to 1999 21 9 to 37 28 17 to 42
Figure 1
Overall age-standardized relative survival in relation to time since  diagnosis Overall age-standardized relative survival in relation to time since diag-
nosis. Overall age-standardized relative survival of women diagnosed 
with breast cancer from 1980 to 1999 in Singapore and in Stockholm 
in relation to time since diagnosis.Breast Cancer Research    Vol 11 No 1    Tan et al.
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registry, however, to obtain detailed clinical information from
the clinical case notes. The proportion of unknown disease
stage was hence worst in the early 1990s, only 52% with com-
plete clinical staging for cases in 1990 to 1994 (P < 0.001),
and this improved in the last 5 years of the study. This incom-
plete staging is probably random, however, as the age-stand-
ardized survival for the Singaporean women with unknown
disease stage was comparable with the overall survival of
those with stage information (data not shown). The ethnic dis-
Figure 2
Age-standardized relative survival by the stage of cancer in relation to  time since diagnosis Age-standardized relative survival by the stage of cancer in relation to 
time since diagnosis. Age-standardized relative survival of women diag-
nosed with breast cancer from 1980 to 1999 in Singapore and in 
Stockholm by the stage of cancer in relation to time since diagnosis.
Figure 3
Five-year age-standardized relative survival by stage of breast cancer  and calendar year of diagnosis Five-year age-standardized relative survival by stage of breast cancer 
and calendar year of diagnosis. Five-year age-standardized relative sur-
vival of women with breast cancer in Singapore and in Stockholm by 
the stage of breast cancer and the calendar year of diagnosis (3-year 
centered moving average).Available online http://breast-cancer-research.com/content/11/1/R4
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tribution between the two groups was not different (P  =
0.576), and the age distribution by the period of diagnosis was
also similar except for fewer women between 35 and 54 years
old being diagnosed in 1985 to 1989 (P = 0.032).
The accuracy of staging could have affected the stage distri-
bution and should be regarded with caution. It is possible that,
in the earlier years, node-positive tumors were underdiag-
nosed and falsely classified as being localized, and hence
appeared to have poorer survival. The axillary dissection and
histologic assessment of specimens may have been less thor-
ough. The proportion of such cases is unknown in this study,
but is probably small. Active screening for distant metastases
at the time of initial diagnosis, a practice routinely adopted in
Singapore but not in Sweden, can induce stage migration and
increase the stage-dependent survival in all stages to the ben-
efit of the Singaporean women; Swedish women with clinically
occult distant metastasis may have been understaged. Earlier
diagnosis by screening can cause lead-time bias and falsely
depict better survival, where the time of diagnosis was earlier
while the death from breast cancer was not delayed or
avoided. Without a nationwide breast screening program in
Singapore, the lead-time bias could not be an advantage for
Singapore to explain the decreased risk of death for 1990 to
1999. Opportunistic screening is available and widely used in
clinics, however, as healthcare and health awareness
improved with the socioeconomic status of Singapore in the
1990s. Length-time bias may exist and is a limitation in this
comparison since screening is probably more extensive, hav-
ing been implemented early in Stockholm. We would expect a
more favorable outcome in the Swedish population when a
greater proportion of slow-growing breast cancer with good
prognosis is being diagnosed [26]. This is difficult to quantify
without a randomized trial.
The observation of the overall survival advantage in Stockholm
(Figure 1) occurs because the proportion of women diag-
nosed with a local cancer (80%) was larger than that of Sin-
gaporean women (51%) (Table 1). This larger diagnosis is a
consequence of established organized mammographic
screening in Sweden since the late 1980s, which became
nationwide in the mid-1990s. This advantage was present
Table 3
Poisson regression: excess risk of death by stratified by country
Singapore Stockholm
Hazard ratio 95% confidence interval P value Hazard ratio 95% confidence interval P value
Year of follow-up
1 year 1.00 (Reference) 1.00 (Reference)
2 years 1.32 1.14 to 1.51 <0.001 1.69 1.47 to 1.94 <0.001
3 years 1.21 1.04 to 1.40 0.013 1.90 1.65 to 2.18 <0.001
4 years 1.12 0.95 to 1.31 0.178 1.71 1.48 to 1.98 <0.001
5 years 0.96 0.81 to 1.14 0.631 1.84 1.59 to 2.14 <0.001
Age group
<35 years 1.00 (Reference) 1.00 (Reference)
35 to 54 years 0.65 0.54 to 0.78 <0.001 0.71 0.57 to 0.88 0.002
45 to 54 years 0.66 0.55 to 0.79 <0.001 0.56 0.45 to 0.69 <0.001
55 to 64 years 0.91 0.75 to 1.10 0.314 0.60 0.49 to 0.74 <0.001
65 to 74 years 0.77 0.62 to 0.96 0.022 0.78 0.64 to 0.96 0.019
75+ years 1.06 0.81 to 1.39 0.673 0.89 0.71 to 1.10 0.281
Stage
Local 1.00 (Reference) 1.00 (Reference)
Regional 3.66 3.22 to 4.17 <0.001 4.02 3.66 to 4.41 <0.001
Distant 13.29 11.41 to 15.48 <0.001 17.25 15.09 to 19.71 <0.001
Period of diagnosis
1980 to 1989 1.00 (Reference) 1.00 (Reference) <0.001
1990 to 1999 0.53 0.48 to 0.58 <0.001 0.91 0.83 to 0.99 0.027Breast Cancer Research    Vol 11 No 1    Tan et al.
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throughout the study period as more Swedish women were
consistently being diagnosed with localized disease (Table 1).
The effect of stage distribution being a key reason for the dif-
ference in survival of the Singaporean population compared
with the Stockholm population is reminiscent of a study from
Stockholm in the period 1961 to 1973 [27], and is again
reflected in a more recent comparison of screened and non-
screened Danish and Swedish populations [28].
When compared across the period of diagnosis, there was
decreased risk of death in the premenopausal women in both
populations and in the postmenopausal women in Singapore,
signifying improvements in both countries. In the later period
where nationwide screening was still not present in Singa-
pore, the Singaporean women were performing no worse than
the Swedish women (Figure 3). Interestingly, after adjusting
for potential confounders, there was a mean 19% (CI 6% to
30%) decrease in risk of death in the premenopausal and a
mean 22% (CI 11% to 32%) decrease in the postmenopausal
Singaporean women as compared with Swedish women dur-
ing the period 1990 to 1999 (Table 4).
A significant change in Singapore during the study period is
that Singapore underwent much economic restructuring in the
1980s and 1990s, resulting in marked economic improve-
ments over these two decades [14]. The increase in Gross
Domestic Product was 725% in Singapore and 190% in Swe-
den from 1980 to 1999 (International Monetary Fund statis-
tics). This resulted in improved living standards, improved
education and presumably better awareness of the disease,
and in better healthcare including breast screening – albeit
opportunistic – in Singapore. Like Sweden, Singapore enjoys
a large network of affordable primary healthcare services that
refer to government-funded (Sweden) or heavily subsidized
(Singapore) hospital and specialist care services. Healthcare
indicators such as life expectancy, the infant mortality rate and
the hospital to population ratio are comparable [15,16].
This restructuring coincided with a time trend towards less
advanced tumors being diagnosed, where a small but definite
increase in women with localized disease and a corresponding
decrease in women with regional disease over the study
period were observed in Singapore (Table 1). This is also sup-
ported by the finding of an increase in incidence of ductal car-
cinoma in situ from 0.4% in 1983 to 1989 to 8.1% in 1999
(Singapore Cancer Registry statistics), an indicator of results
Table 4
Poisson regression: excess risk of death between countries stratified by age and period of diagnosis
1980 to 1989 1990 to 1999
Hazard ratio 95% confidence interval P value Hazard ratio 95% confidence interval P value
Age  50 years
Countrya
Stockholm 1.00 (Reference) 1.00 (Reference)
Singapore 1.26 1.08 to 1.47 0.003 0.81 0.70 to 0.94 0.007
Age >50 years
Countrya
Stockholm 1.00 (Reference) 1.00 (Reference)
Singapore 1.48 1.29 to 1.69 <0.001 0.78 0.68 to 0.89 <0.001
aAdjusted for year of follow-up and disease stage.
Figure 4
Incidence, 5-year cause-specific mortality and 5-year age-standardized  relative survival ratios across the year of diagnosis Incidence, 5-year cause-specific mortality and 5-year age-standardized 
relative survival ratios across the year of diagnosis. Trends in incidence, 
5-year cause-specific mortality and 5-year age-standardized relative 
survival ratios in patients with breast cancer in Singapore and in Stock-
holm across the calendar year of diagnosis. IR, Incidence Rate; MR, 
Mortality Rate; RSR, Relative Survival Ratio.Available online http://breast-cancer-research.com/content/11/1/R4
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of increased mammographic screening. In addition, the
improvement in survival in each stage across the periods –
including for those with distant metastasis, albeit small (Figure
3 and Table 2) – would suggest improvement in treatment
options with the use of adjuvant therapy with antiestrogen and
chemotherapy that had become more standardized in the
1990s in Singapore. The quality of the healthcare and treat-
ment routines probably did not differ to a larger extent or to the
benefit of Swedish women in the later part of the follow-up
period. Treatment details are not available for these patients
and are a study limitation. Treatment of breast cancer, how-
ever, was standardized under institutional practice in both
Stockholm and Singapore in the 1990s, and this was compa-
rable (personal communication with P Hall, Stockholm, and
CY Wong, Singapore). The survival equivalence after stratifi-
cation by stage (Figure 2) suggests that both Singaporean
women and Swedish women respond similarly to the treat-
ments given.
Antiestrogen treatment has been well established since the
1990s. Seventy-seven percent of the Swedish women had
tumors that were positive for the ER. This is in contrast to a
more recent report of 55% Singaporean women from a local
institution [29], not different from a series from the largest hos-
pital in Singapore (unpublished data). The Swedish women
would be expected to perform better in each stage if the
receptor status was indeed stage independent. The present
study could not demonstrate the postulated survival advan-
tage of ER-positive tumors, or perhaps the effect of this factor
is small. Nevertheless, the improvement of survival only in the
premenopausal Swedish women across the period is probably
the result of increased aggressiveness in treating this group of
women, with tamoxifen as well as chemotherapy.
Until the 1970s Singaporean women had a mean fertility rate
of approximately five children compared with two children for
Swedish women [5,30]. This higher fertility in the earlier Sin-
gaporean birth cohort contributed to the low incidence of
breast cancer, especially postmenopausal breast cancer.
Unfortunately, this may have resulted in a higher proportion of
premenopausal breast cancer (Table 1), which is more likely to
be ER-negative with poorer survival. Parity may therefore not
only affect risk [4,31-33], but also the prognosis of breast can-
cer. The present study, however, is limited by the absence of
information of the tumor receptor status as well as the unavail-
ability of complete parity information in the Singaporean
cohort. It remains unsettled whether risk factors of breast can-
cer that influence the cancer incidence and malignant pheno-
type will affect the prognosis.
Other factors such as body mass index, diet, and other behav-
ioral, cultural, environmental, or genetic differences are factors
that have been known to affect incidence, but the effect on
prognosis is less known [34], and is not available in this study.
Singapore, however, reported fewer women who smoke –
3.2% (2004 National Health Survey statistics) compared with
29% of Swedish women in 1980, and 18% in 2005 (Sweden
statistics). Only about 6% of postmenopausal women in Sin-
gapore are on hormonal replacement therapy for menopause
[35], compared with 21% of women in Sweden [36].
As advocated by Dickman and Adami, the trends in survival
were interpreted in context with the incidence and mortality
rates to evaluate the progress against cancer [37]. As com-
pared with the Swedish women who had enjoyed a more sta-
ble economy during this period, the dramatic increase in
incidence in Singapore was probably the result of aggressive
screening practices that came with increased awareness, bet-
ter education, and improved healthcare facilities as our econ-
omy improved, even without a national screening program. The
relatively stable mortality and the corresponding marked
increase in the survival ratios in the Singaporean women prob-
ably represented improved treatment options. The more supe-
rior survival ratios in the earlier years of diagnosis in the
Swedish women remained relatively stable, while the increase
in incidence coincided with a less dramatic change in the sur-
vival compared with the Singaporean women (Figure 4).
Conclusions
The survival of women with breast cancer in each disease
stage was comparable between the Singapore and Stockholm
cohorts. We hypothesize that better economic status associ-
ated with increased awareness of the disease, better access
to screening routines or healthcare quality and options, seen
in Stockholm and in Singapore only in the later decade, offer
the main explanation for the prognostic differences and
similarities.
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